<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02301390</url>
  </required_header>
  <id_info>
    <org_study_id>B14-02-34-05</org_study_id>
    <nct_id>NCT02301390</nct_id>
  </id_info>
  <brief_title>INTERVENE: Indian Trial of Endocardial Ventricular Substrate Ablation to Prevent Recurrent VT Events</brief_title>
  <acronym>INTERVENE</acronym>
  <official_title>INTERVENE: Indian Trial of Endocardial Ventricular Substrate Ablation to Prevent Recurrent VT Events</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biosense Webster, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study to is being conducted in India to determine the role of catheter-based ablation
      for ventricular tachycardia (VT) in post- heart attack patients who meet established
      guidelines for implantable cardiodefibrillator (ICD) implantation, but cannot afford it.
      These patients would be started on chronic Amiodarone therapy, which has been shown to be
      effective but can often lead to multiple side effects.

      Patients will therefore be randomized in an even proportion to either a) the control group,
      receiving chronic Amiodarone therapy, or the study group, undergoing catheter ablation of VT
      in addition to chronic Amiodarone therapy.

      This trial will serve as a representative model for the developing world.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sudden cardiac death (SCD) accounts for approximately 50% of all cardiac death, representing
      an estimated annual incidence ranging from 250,000 to 350,000 cases in the United States. The
      pathophysiologic mechanism for sudden death in the majority of these patients is thought to
      be ventricular tachycardia (VT) related to coronary artery disease (CAD), which can then
      degenerate to ventricular fibrillation (VF). Patients who survive an initial episode of VT/VF
      are prone to an extremely high incidence of recurrent life-threatening events (~25% at one
      year). Even in patients without a history of VT/VF, the presence of CAD and left ventricular
      (LV) dysfunction confers a two-year mortality rate of 22%. If VT is inducible at
      electrophysiological testing, the two-year mortality is ~30%.

      The pathogenesis of VT in the setting of CAD is reentry in the area of the scarred
      myocardium. After an MI, the tissue can be broadly divided into three zones: the dense scar,
      the surrounding live myocardial tissue, and the intervening border zone. After a myocardial
      infarction (MI), the &quot;border zone&quot; between dense scar and live tissue contains
      electrically-active live myocardial fibrils interspersed in areas of infarcted, fibrotic
      tissue—setting the stage for local reentrant circuits that result in VT.

      The use of antiarrhythmic medications (AADs) to suppress the occurrence/recurrence of VT/VF
      in these high-risk patients has been mostly disappointing. In large clinical trials, most
      AADs have not only proved to be inefficacious, but to actually increase mortality. The one
      potential exception appears to be Amiodarone: one study suggests some mortality benefit
      (GESICA), while others suggest that Amiodarone provides significant antiarrhythmic benefits
      without a change in mortality (EMIAT, CAMIAT, SCD-HeFT). However, even the use of Amiodarone
      is plagued with multiple organ toxicities, ranging from pulmonary fibrosis to hepatitis, and
      thyroid dysfunction.

      An important alternative to such questionably efficacious antiarrhythmics is the implantable
      cardio-defibrillator (ICD), which can accurately and effectively detect and terminate VT/VF,
      resulting in a significant mortality benefit in both the primary and secondary prevention of
      sudden cardiac death. Yet, despite these beneficial results, ICD implantation cannot be
      considered a cure for VT. In addition, it is common for patients to experience painful
      high-voltage shocks secondary to recurrent ventricular arrhythmias, or to lose consciousness
      prior to the delivery of therapy. Moreover, the considerable cost of ICDs severely limits
      their availability in the developing world—where public and/or private health insurance
      systems are rudimentary at best, and where the incidence of coronary artery disease is four
      times higher than that of the developed world—highlighting the urgency of establishing an
      alternative therapy for post-MI patients with ventricular arrhythmias that is both accessibly
      and effective.

      One such option may be catheter ablation of ventricular arrhythmias. It has been well
      described that for hemodynamically-stable VT circuits, careful ventricular mapping to
      identify sites critical to the maintenance of a given circuit, followed by discrete
      applications of catheter-based radiofrequency (RF) energy, can effectively eliminate VT.

      This strategy mocks surgical approaches that have been used extensively since the late 1970s
      for modification of the arrhythmogenic substrate in patients with chronic myocardial
      infarction. Since the location of the reentrant circuit is most often located at the junction
      of the normal and scarred myocardium, two effective general strategies were developed over
      time: a) subendocardial resection—involving surgical removal of the subendocardial layer
      containing the arrhythmogenic substrate in this border zone, and b) encircling endocardial
      ventriculotomy—consisting of the placement of a circumferential surgical lesion through the
      border zone and, presumably, interrupting potential VT circuits. When performed at
      experienced centers, the long-term freedom from malignant VT/VF after surgery is &gt;90%.
      However, the significant mortality (3-14%) and morbidity associated with this invasive
      procedure has curtailed its use in general practice.

      The less invasive, catheter approach to substrate modification relies on electroanatomical
      mapping systems that create a high fidelity representation of the endocardium, allowing for
      the reconstruction and electronic manipulation of an endocardial cast of the ventricular
      chamber that carefully delineates the normal and abnormal tissues. This is based on the
      observation that during normal sinus rhythm, there are distinguishing characteristics of the
      endocardial electrogram (EGM) of normal and abnormal tissue: abnormal tissue manifests lower
      voltage amplitude, prolonged EGM duration, and the presence of late and fractionated
      potentials. Marchlinski and colleagues reported in a seminal study that by using a
      substrate-mapping strategy, catheter-based RF ablation lesions directed in a linear fashion
      were effective in controlling scar-related drug-refractory unstable VT. Furthermore, using
      this high-density electroanatomical mapping 1) this strategy can be utilized to localize the
      arrhythmogenic substrate in the majority of patients with a history of myocardial infarction
      and sustained ventricular tachyarrhythmia's, and 2) RF ablation using an irrigated-tip
      ablation catheter can be effectively and safely used to modify the arrhythmogenic substrate
      to render VT non-inducible even in the presence of multiple VT morphologies.

      The favorable results in these non-randomized reports prompted the initiation of SMASH-VT
      (Substrate Mapping &amp; Ablation in Sinus Rhythm to Halt Ventricular Tachycardia Trial); a
      prospective randomized clinical trial to objectively assess the clinical utility of substrate
      ablation of scar-related VT. This trial was a randomized-controlled trial examining the role
      of substrate mapping and RF ablation in the primary prevention of ICD shocks in patients
      presenting with clinically life-threatening VT/VF. That is, patients with a history of MI,
      and who survive an episode of VT/VF are at high-risk for recurrent VT and thus treated with
      ICDs (in essence, these patients meet AVID/CIDS/CASH criteria). In normal clinical practice,
      these patients are not routinely treated with adjuvant medications because of their
      proarrhythmic potential and side effects. In addition to an ICD and routine clinical care,
      these patients were additionally randomized in SMASH-VT to substrate-based catheter ablation.
      This catheter ablation group underwent electroanatomic mapping to delineate the endocardial
      infarct margins (CARTO, Biosense-Webster, Inc.). Substrate modification was then performed
      targeting the exit sites of induced VTs and/or late potentials within the scar using standard
      or irrigated radiofrequency ablation catheters.

      As published in late 2007 (Reddy et al, NEJM, 357:2657), the 30-day post-ablation mortality
      was zero, and there was no significant change in ventricular function or functional class
      during follow up. During an average follow-up of 22.5±5.5 months, appropriate defibrillator
      therapy (anti-tachycardia pacing and shocks) occurred in 21 control (33%) and 8 ablation
      (12%) patients (p=0.007 by the log rank test). Of these, appropriate defibrillator shocks
      alone occurred in 20 control (31%) and 6 ablation (9%) patients (p=0.003). Mortality was not
      increased in the ablation arm (control 17%, ablation 9%; p=0.29); indeed, there was a trend
      to decreased mortality in the ablation arm. Thus, the SMASH-VT study revealed several
      important points: 1) adjuvant substrate based catheter ablation is feasible in this patient
      population, 2) use of a saline-irrigated RF ablation catheter for this ablation strategy is
      safe, and 3) this strategy decreases subsequent ICD therapies in post-myocardial infarction
      patients receiving defibrillators for the secondary prevention of sudden death.

      The favorable results of SMASH-VT, combined with considerable technical and scientific
      improvements in catheter ablation of scar-related VT, also raise the possibility that the
      therapeutic benefit of ablation may be extrapolated to similar patients in the developing
      world, who have had an MI and have survived a ventricular arrhythmic event, but are unable to
      afford an ICD. This is of particular importance because such patients are typically treated
      with chronic Amiodarone therapy—a strategy with an unestablished mortality benefit and
      significant side effects.

      The investigators therefore propose a randomized clinical trial, in which India—a nation with
      a population of 1.2 billion—will serve as a representative model for the developing world.
      The study will evaluate the safety and efficacy of adjunctive catheter ablation in
      post-myocardial infarction patients who have additionally survived a ventricular arrhythmic
      event, and would be initiated on chronic Amiodarone therapy because of an inability to afford
      ICD therapy. Patients will therefore be randomized in an even proportion to either a) the
      control group, receiving chronic Amiodarone therapy, or the study group, undergoing catheter
      ablation of VT in addition to chronic Amiodarone therapy.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    could not meet enrollment goal
  </why_stopped>
  <start_date type="Actual">October 2009</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Who Were Free From All-cause Mortality, Sustained VT or Cardiac Arrest</measure>
    <time_frame>at 24 months</time_frame>
    <description>Number of participants who had no occurrences of all-cause mortality, sustained ventricular tachycardia (VT) and cardiac arrest at 24 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participant Who Died</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Number of subjects that die within 30 days or die by 24 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventricular Arrhythmic Events</measure>
    <time_frame>at 24 months</time_frame>
    <description>Total number of ventricular arrhythmic events, compared between the 2 treatment arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in LV Ejection Fraction</measure>
    <time_frame>baseline and 24 months</time_frame>
    <description>Change in left ventricle (LV) ejection fraction between paired measurements recorded at 24 months as compared to baseline</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Ventricular Tachycardia</condition>
  <arm_group>
    <arm_group_label>Amiodarone only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The control group will receive amiodarone only.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amiodarone + Catheter Ablation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The experimental group will receive amiodarone plus catheter VT ablation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amiodarone</intervention_name>
    <description>Amiodarone is a Class III antiarrhythmic agent.</description>
    <arm_group_label>Amiodarone + Catheter Ablation</arm_group_label>
    <arm_group_label>Amiodarone only</arm_group_label>
    <other_name>Cordarone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Catheter Ablation</intervention_name>
    <description>The ablation procedure uses radiofrequency energy to destroy cardiac tissue at the origin of the arrhythmia.</description>
    <arm_group_label>Amiodarone + Catheter Ablation</arm_group_label>
    <other_name>VT catheter ablation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥ 18 and ≤ 85 years of age

          -  History of a remote MI (≥1 month)

          -  Survival of a ventricular arrhythmic event (VT/VF) that would mandate placement of an
             implantable cardioverter-defibrillator (ICD) (Patients who experience a ventricular
             arrhythmic event (VT/VF) while already being treated with Amiodarone (100-200 mg/day)
             are not excluded from the study. This is permitted provided that the patient had been
             treated with Amiodarone for at least 2 months prior to experiencing the index VT/VF
             event. These patients are randomized to either a higher dose of Amiodarone (e.g.,
             100mg/day -&gt; 200mg/day or 200mg/day -&gt; 400mg/day) or a higher dose of Amiodarone plus
             catheter ablation.)

          -  Patient cannot afford an ICD and thus has been planned for treatment with Amiodarone
             (or an increased dose of Amiodarone)

          -  Ability to understand the requirements of the study

          -  Willingness to adhere to study restrictions and comply with all post- procedural
             follow-up requirements

        Exclusion Criteria:

          -  Patients with NYHA class IV congestive heart failure

          -  Prior ablation for a ventricular arrhythmia

          -  Presence of an LV thrombus

          -  Contraindication to anticoagulation

          -  Inability to access the endocardium because of mechanical mitral and aortic valve

          -  Life expectance &lt;1 year for any medical condition
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vivek Reddy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Calambur Narasimhan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CARE Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CARE Institute of Medical Science</name>
      <address>
        <city>Ahmedabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CARE Hospital</name>
      <address>
        <city>Hyderabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER)</name>
      <address>
        <city>Puducherry</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>November 21, 2014</study_first_submitted>
  <study_first_submitted_qc>November 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2014</study_first_posted>
  <results_first_submitted>January 14, 2020</results_first_submitted>
  <results_first_submitted_qc>January 14, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 27, 2020</results_first_posted>
  <last_update_submitted>January 14, 2020</last_update_submitted>
  <last_update_submitted_qc>January 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Icahn School of Medicine at Mount Sinai</investigator_affiliation>
    <investigator_full_name>Vivek Reddy</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>INTERVENE</keyword>
  <keyword>Ventricular tachycardia</keyword>
  <keyword>India</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Tachycardia, Ventricular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amiodarone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 22, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/90/NCT02301390/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Amiodarone Only</title>
          <description>Amiodarone is a Class III antiarrhythmic agent.</description>
        </group>
        <group group_id="P2">
          <title>Amiodarone + Catheter Ablation</title>
          <description>Amiodarone is a Class III antiarrhythmic agent.
Catheter VT Ablation: The ablation procedure uses radiofrequency energy to destroy cardiac tissue at the origin of the arrhythmia.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Procedure not completed</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Missed multiple visits</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>study terminated</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Amiodarone Only</title>
          <description>Amiodarone is a Class III antiarrhythmic agent.</description>
        </group>
        <group group_id="B2">
          <title>Amiodarone + Catheter Ablation</title>
          <description>Amiodarone is a Class III antiarrhythmic agent.
Catheter VT Ablation: The ablation procedure uses radiofrequency energy to destroy cardiac tissue at the origin of the arrhythmia.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="27"/>
            <count group_id="B2" value="26"/>
            <count group_id="B3" value="53"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.9" spread="10.7"/>
                    <measurement group_id="B2" value="53.8" spread="10.4"/>
                    <measurement group_id="B3" value="54.3" spread="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Were Free From All-cause Mortality, Sustained VT or Cardiac Arrest</title>
        <description>Number of participants who had no occurrences of all-cause mortality, sustained ventricular tachycardia (VT) and cardiac arrest at 24 months</description>
        <time_frame>at 24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Amiodarone Only</title>
            <description>Amiodarone is a Class III antiarrhythmic agent.</description>
          </group>
          <group group_id="O2">
            <title>Amiodarone + Catheter Ablation</title>
            <description>Amiodarone is a Class III antiarrhythmic agent.
Catheter VT Ablation: The ablation procedure uses radiofrequency energy to destroy cardiac tissue at the origin of the arrhythmia.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Were Free From All-cause Mortality, Sustained VT or Cardiac Arrest</title>
          <description>Number of participants who had no occurrences of all-cause mortality, sustained ventricular tachycardia (VT) and cardiac arrest at 24 months</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participant Who Died</title>
        <description>Number of subjects that die within 30 days or die by 24 months.</description>
        <time_frame>up to 24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Amiodarone Only</title>
            <description>Amiodarone is a Class III antiarrhythmic agent.</description>
          </group>
          <group group_id="O2">
            <title>Amiodarone + Catheter Ablation</title>
            <description>Amiodarone is a Class III antiarrhythmic agent.
Catheter VT Ablation: The ablation procedure uses radiofrequency energy to destroy cardiac tissue at the origin of the arrhythmia.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participant Who Died</title>
          <description>Number of subjects that die within 30 days or die by 24 months.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>within 30 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ventricular Arrhythmic Events</title>
        <description>Total number of ventricular arrhythmic events, compared between the 2 treatment arms.</description>
        <time_frame>at 24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Amiodarone Only</title>
            <description>Amiodarone is a Class III antiarrhythmic agent.</description>
          </group>
          <group group_id="O2">
            <title>Amiodarone + Catheter Ablation</title>
            <description>Amiodarone is a Class III antiarrhythmic agent.
Catheter VT Ablation: The ablation procedure uses radiofrequency energy to destroy cardiac tissue at the origin of the arrhythmia.</description>
          </group>
        </group_list>
        <measure>
          <title>Ventricular Arrhythmic Events</title>
          <description>Total number of ventricular arrhythmic events, compared between the 2 treatment arms.</description>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in LV Ejection Fraction</title>
        <description>Change in left ventricle (LV) ejection fraction between paired measurements recorded at 24 months as compared to baseline</description>
        <time_frame>baseline and 24 months</time_frame>
        <population>Data for only those who had two time points LV ejection fraction data</population>
        <group_list>
          <group group_id="O1">
            <title>Amiodarone Only</title>
            <description>Amiodarone is a Class III antiarrhythmic agent.</description>
          </group>
          <group group_id="O2">
            <title>Amiodarone + Catheter Ablation</title>
            <description>Amiodarone is a Class III antiarrhythmic agent.
Catheter VT Ablation: The ablation procedure uses radiofrequency energy to destroy cardiac tissue at the origin of the arrhythmia.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in LV Ejection Fraction</title>
          <description>Change in left ventricle (LV) ejection fraction between paired measurements recorded at 24 months as compared to baseline</description>
          <population>Data for only those who had two time points LV ejection fraction data</population>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.85" spread="6.32"/>
                    <measurement group_id="O2" value="8" spread=".31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Amiodarone Only</title>
          <description>Amiodarone is a Class III antiarrhythmic agent.</description>
        </group>
        <group group_id="E2">
          <title>Amiodarone + Catheter Ablation</title>
          <description>Amiodarone is a Class III antiarrhythmic agent.
Catheter VT Ablation: The ablation procedure uses radiofrequency energy to destroy cardiac tissue at the origin of the arrhythmia.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>VT recurrrence</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Heart Failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>LV failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Subclinical/Sub radiological ILD</sub_title>
                <description>Interstitial Lung Disease (ILD)</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>CVA</sub_title>
                <description>Cerebrovascular accident (CVA)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Amiodarone induced liver injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Hepatic enephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Motor aphasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary edema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Transient AV block while crossing the Aortic Valve</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Frequent loose stools</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Frequent loose stools</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic progressive gingivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Viral Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>right foot injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Right arm ecchymosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Betsy Ellsworth, Research Program Director</name_or_title>
      <organization>Icahn School of Medicine at Mount Sinai</organization>
      <phone>212-824-8902</phone>
      <email>betsy.ellsworth@mountsinai.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

